Author:
Shenoy Padmanabha,Nalianda Kaveri K.
Publisher
Springer Nature Singapore
Reference24 articles.
1. De Keyser F. Choice of biologic therapy for patients with rheumatoid arthritis: the infection perspective. Curr Rheumatol Rev. 2011;7:77–87.
2. Handa R, Upadhyaya S, Kapoor S, et al. Tuberculosis and biologics in rheumatology: a special situation. Int J Rheum Dis. 2017;20:1313–25.
3. Cantini F, Prignano F, Goletti D. Restarting biologics and Management of Patients with flares of inflammatory rheumatic disorders or psoriasis during active tuberculosis treatment. J Rheumatol. 2014;91:78–82.
4. Cantini F, Nannini C, Niccoli L, et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmune Rev. 2015;14(7):503–9.
5. Holroyd CR, Seth R, Bukhari M, et al. The British Society of Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. Rheumatology. 2019;58:e3–e42.